The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. The portion of an entity not wholly-owned by the Company is presented as non-controlling interests. All significant intercompany balances and transactions are eliminated in consolidation. The financial statements of the Company's subsidiaries are prepared using accounting policies consistent with those of the Company. Reclassifications Recent Accounting Pronouncements 13 The Compa ...

Financial Performance - Cano Health reported a net loss of $28.15 million for the three months ended March 31, 2023, compared to a net loss of $32.44 million for the same period in 2022[50]. - The company reported a net loss of $60,585,000 for the three months ended March 31, 2023, compared to a net loss of $85,000 for the same period in 2022[87]. - The net loss attributable to Class A common stockholders for Q1 2023 was $28.2 million, compared to a net income of $0.7 million in Q1 2022[109]. - Net loss for Q1 2023 was $60.6 million, compared to a net loss of $85,000 in Q1 2022[1]. - Adjusted EBITDA for the three months ended March 31, 2023, was $4,979,000, down from $29,191,000 in the same period last year[161]. Revenue and Growth - Total revenue for the three months ended March 31, 2023, was $866.9 million, a 23% increase from $704.3 million in the same period of 2022[109]. - Capitated revenue increased to $841.1 million in Q1 2023, up from $674.4 million in Q1 2022, reflecting a significant growth in patient enrollment[109]. - Total members increased to 388,667, a 44.3% growth from 269,333 in the previous year[144]. - Capitated revenue for Q1 2023 was $841.1 million, a 24.7% increase from $674.4 million in Q1 2022, driven by a 42.6% increase in total member months[122]. Expenses and Costs - Total operating expenses for Q1 2023 were $906.4 million, compared to $715.8 million in Q1 2022, primarily driven by increased third-party medical costs of $708.3 million[109]. - Third-party medical costs increased by 32.2% to $708.3 million in Q1 2023, compared to $535.8 million in Q1 2022[123]. - Operating expenses rose to $906,438,000, reflecting a 26.6% increase from $715,793,000 in the prior year[146]. - Interest expense rose by 76.9% to $23.5 million in Q1 2023, up from $13.3 million in Q1 2022[126]. - Depreciation and amortization expense increased by 43.0% to $27.2 million in Q1 2023, compared to $19.0 million in Q1 2022[124]. Cash Flow and Liquidity - Cash used in operating activities for the three months ended March 31, 2023, was $29,470,000, an improvement from $37,203,000 in the prior year[87]. - The company experienced a net cash inflow of $56,488,000 from financing activities during the three months ended March 31, 2023[87]. - The company’s cash, cash equivalents, and restricted cash at the end of the period were $44,888,000, down from $113,052,000 at the beginning of the year[87]. - Cash and cash equivalents increased to $44.9 million as of March 31, 2023, from $27.3 million as of December 31, 2022[106]. - The company expects to incur approximately $81,000,000 in cash interest payments in 2023[154]. Equity and Stock - The company issued 21,620,941 shares of Class A common stock in connection with a $150 million senior secured term loan, with an interest rate of 14% per annum until February 2025[35]. - The unrecognized compensation cost of outstanding restricted stock units (RSUs) as of March 31, 2023, was $61.1 million for service-based awards and $1.0 million for performance-based awards[43]. - Cano Health's total equity increased to $504.4 million as of March 31, 2023, up from $494.3 million at the end of 2022[50]. - The company has a weighted average remaining service period of 1.3 years for service-based RSUs and 1.1 years for performance-based RSUs[43]. Operational Strategy - The company aims to expand its medical center base, leveraging technology solutions to improve patient care and reduce healthcare costs[30]. - CanoPanorama, the company's proprietary population health management platform, enhances clinical care by providing healthcare providers with a comprehensive view of their members[53]. - The company is focused on improving health outcomes and patient experience, aligning incentives among patients, payors, and providers[30]. - The company utilizes stop-loss insurance to mitigate exposure to large medical claims[58]. - The company focuses on high-quality care, membership growth, and effective medical cost management to meet payor expectations[72]. - The company leverages a proprietary technology platform to deliver high-quality healthcare services, particularly in underserved communities[94]. - The company plans to significantly reduce investments in new medical centers in 2023[57]. - As of March 31, 2023, the company operates 170 medical centers, indicating a strong capacity for new members[57].

Our failure to pay the rent or otherwise comply with the provisions of any of our lease agreements could result in an "event of default" under such lease agreement and agreements for our indebtedness. Upon an event of default, remedies available to our landlords generally include, without limitation, terminating such lease agreement, repossessing and reletting the leased properties and requiring us to remain liable for all obligations under such lease agreement, including the difference between the rent und ...

[PART I FINANCIAL INFORMATION](index=3&type=section&id=PART%20I%20FINANCIAL%20INFORMATION) [Cautionary Note Regarding Forward-Looking Statements](index=3&type=section&id=Cautionary%20Note%20Regarding%20Forward-Looking%20Statements) This section details forward-looking statements, emphasizing their inherent risks and the potential for actual results to differ materially from expectations - Forward-looking statements cover areas such as the ability to recognize benefits from acquisitions, financial performance, strategy changes, regulatory impacts, membership growth, and the ability to control medical costs[8](index=8&type=chunk) - Key risks that could cause actual results to differ include the ability to maintain NYSE listing, security price volatility, economic downturns, the need for additional capital, and difficulties in managing growth[11](index=11&type=chunk) [Financial Statements (Unaudited)](index=5&type=section&id=Item%201.%20Financial%20Statements) The unaudited financial statements reveal increased assets and liabilities, a net loss of **$112.0 million** for Q3 2022, and a significant decrease in cash and cash equivalents [Condensed Consolidated Balance Sheets](index=5&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) The balance sheet shows total assets at **$2.20 billion**, a sharp decline in cash to **$24.1 million**, and an increase in total liabilities to **$1.41 billion** Condensed Consolidated Balance Sheet Highlights (in thousands) | Account | Sep 30, 2022 | Dec 31, 2021 | | :--- | :--- | :--- | | **Assets** | | | | Cash, cash equivalents and restricted cash | $24,097 | $163,170 | | Accounts receivable, net | $202,037 | $133,433 | | Goodwill | $787,885 | $769,667 | | **Total Assets** | **$2,196,139** | **$2,143,539** | | **Liabilities & Equity** | | | | Notes payable, net | $914,394 | $915,266 | | **Total Liabilities** | **$1,413,105** | **$1,344,971** | | **Total Stockholders' Equity** | **$783,034** | **$798,568** | [Condensed Consolidated Statements of Operations](index=6&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations) Q3 2022 revenue increased to **$665.0 million**, but net loss widened to **$112.0 million**, with nine-month revenue reaching **$2.06 billion** and net loss at **$126.7 million** Statement of Operations Highlights (in thousands) | Metric | Q3 2022 | Q3 2021 | Nine Months 2022 | Nine Months 2021 | | :--- | :--- | :--- | :--- | :--- | | **Total Revenue** | **$665,028** | **$498,931** | **$2,058,543** | **$1,117,114** | | Capitated Revenue | $625,895 | $473,763 | $1,955,739 | $1,064,604 | | Loss from Operations | ($31,445) | ($33,592) | ($74,231) | ($92,929) | | **Net Loss** | **($112,011)** | **($64,840)** | **($126,660)** | **($117,240)** | | Net Loss per Share (basic) | ($0.23) | ($0.14) | ($0.28) | ($0.11) | [Condensed Consolidated Statements of Cash Flows](index=11&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) Net cash used in operations was **$84.2 million**, investing activities used **$48.2 million**, and overall cash and equivalents decreased by **$139.1 million** Cash Flow Summary (in thousands) | Cash Flow Activity | Nine Months Ended Sep 30, 2022 | Nine Months Ended Sep 30, 2021 | | :--- | :--- | :--- | | Net cash used in operating activities | ($84,158) | ($94,493) | | Net cash used in investing activities | ($48,153) | ($1,112,848) | | Net cash provided by (used in) financing activities | ($6,762) | $1,382,447 | | **Net decrease in cash** | **($139,073)** | **$175,106** | [Notes to Interim Condensed Consolidated Financial Statements](index=14&type=section&id=Notes%20to%20Interim%20Condensed%20Consolidated%20Financial%20Statements) These notes detail accounting policies, business structure, revenue recognition, debt, fair value measurements, and other significant financial disclosures - The company provides value-based medical care, focusing on Medicare Advantage, DCE, ACO, and Medicaid members[37](index=37&type=chunk)[38](index=38&type=chunk)[41](index=41&type=chunk) Revenue Breakdown (Nine Months Ended Sep 30, 2022) | Revenue Stream | Amount (in thousands) | % of Total | | :--- | :--- | :--- | | Medicare Capitated | $1,795,820 | 87.2% | | Other Capitated | $159,919 | 7.8% | | Fee-for-service & Other | $102,804 | 5.0% | | **Total Revenue** | **$2,058,543** | **100.0%** | - During the first nine months of 2022, the company completed seven asset acquisitions for a total purchase price of **$41.7 million**, consisting of cash, deferred payments, and Class A common stock[73](index=73&type=chunk) - Total debt as of September 30, 2022, consists of a **$639.6 million** term loan and **$300.0 million** in senior notes[93](index=93&type=chunk)[97](index=97&type=chunk)[98](index=98&type=chunk) - The company is involved in a class-action lawsuit filed in March 2022, alleging violations of the Securities Exchange Act related to disclosures about due diligence and revenue recognition[165](index=165&type=chunk)[167](index=167&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=37&type=section&id=Item%202.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses significant revenue growth driven by membership and acquisitions, a widening net loss due to increased expenses, and liquidity management [Overview and Key Performance Metrics](index=38&type=section&id=Overview%20and%20Key%20Performance%20Metrics) This section outlines the company's value-based care model and highlights significant growth in membership to **294,596** and medical centers to **151** - The company's business model is built on capitated contracts with major health plans, aligning incentives to improve health outcomes and manage costs effectively[188](index=188&type=chunk)[193](index=193&type=chunk) Key Performance Metrics | Metric | Sep 30, 2022 | Sep 30, 2021 | % Change | | :--- | :--- | :--- | :--- | | Membership | 294,596 | 210,663 | 39.8% | | Medical centers | 151 | 113 | 33.6% | [Results of Operations](index=45&type=section&id=Results%20of%20Operations) Q3 2022 revenue grew **33.3%** to **$665.0 million**, while operating expenses increased, leading to a nine-month net loss of **$126.7 million** despite **84.3%** revenue growth Comparison of Three Months Ended September 30, 2022 and 2021 (in thousands) | Item | Q3 2022 | Q3 2021 | $ Change | % Change | | :--- | :--- | :--- | :--- | :--- | | Total Revenue | $665,028 | $498,931 | $166,097 | 33.3% | | Third-party medical costs | $489,565 | $381,316 | $108,249 | 28.4% | | SG&A Expenses | $111,765 | $76,618 | $35,147 | 45.9% | | Net Loss | ($112,011) | ($64,840) | ($47,171) | 72.7% | Comparison of Nine Months Ended September 30, 2022 and 2021 (in thousands) | Item | 9M 2022 | 9M 2021 | $ Change | % Change | | :--- | :--- | :--- | :--- | :--- | | Total Revenue | $2,058,543 | $1,117,114 | $941,429 | 84.3% | | Third-party medical costs | $1,566,661 | $868,177 | $698,484 | 80.5% | | SG&A Expenses | $314,617 | $158,786 | $155,831 | 98.1% | | Net Loss | ($126,660) | ($117,240) | ($9,420) | 8.0% | [Liquidity and Capital Resources](index=57&type=section&id=Liquidity%20and%20Capital%20Resources) The company's cash decreased to **$24.1 million**, with **$120.0 million** available on its credit facility, and management expects sufficient liquidity for the next 12 months - The company has financed operations through the 2021 Business Combination and debt, expecting to require additional capital for strategic growth initiatives[278](index=278&type=chunk)[279](index=279&type=chunk) Cash Flow Summary (Nine Months Ended Sep 30, in thousands) | Activity | 2022 | 2021 | | :--- | :--- | :--- | | Net cash used in operating activities | ($84,158) | ($94,493) | | Net cash used in investing activities | ($48,153) | ($1,112,848) | | Net cash (used in) provided by financing activities | ($6,762) | $1,382,447 | - Management believes current cash and available credit will fund operations for at least the next 12 months, though this is a forward-looking estimate subject to risks[283](index=283&type=chunk) [Non-GAAP Financial Metrics](index=59&type=section&id=Non-GAAP%20Financial%20Metrics) The company utilizes non-GAAP metrics like Adjusted EBITDA, which significantly increased to **$116.8 million** for the nine months ended September 30, 2022 Reconciliation of Net Loss to Adjusted EBITDA (in thousands) | Metric | Q3 2022 | Q3 2021 | Nine Months 2022 | Nine Months 2021 | | :--- | :--- | :--- | :--- | :--- | | **Net Loss** | **($112,011)** | **($64,840)** | **($126,660)** | **($117,240)** | | Interest, Taxes, D&A | $40,542 | $33,527 | $107,721 | $66,343 | | **EBITDA** | **($71,469)** | **($31,316)** | **($18,943)** | **($50,897)** | | Stock-based compensation | $11,041 | $9,451 | $42,641 | $13,130 | | De novo losses | $24,282 | $10,178 | $59,567 | $24,561 | | Transaction costs | $6,733 | $12,503 | $24,445 | $39,297 | | Other adjustments | $71,866 | $12,833 | $9,132 | ($10,000) | | **Adjusted EBITDA** | **$42,453** | **$13,649** | **$116,842** | **$16,112** | [Quantitative and Qualitative Disclosures About Market Risk](index=60&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) No material changes to market risk disclosures have occurred since the 2021 Annual Report, with interest rate risk remaining the primary exposure - There have been no material changes to the company's market risk disclosures since the 2021 Form 10-K[305](index=305&type=chunk) [Controls and Procedures](index=61&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded that disclosure controls and procedures were ineffective due to un-remediated material weaknesses in financial closing and accounting processes - Management concluded that disclosure controls and procedures were not effective as of September 30, 2022[306](index=306&type=chunk) - The ineffectiveness is due to material weaknesses identified in the 2021 Form 10-K, which have not yet been fully remediated, relating to financial closing, business combination accounting, and personnel expertise[307](index=307&type=chunk)[308](index=308&type=chunk) - Remediation efforts are underway, including enhancing policies, procedures, training, and recruiting skilled personnel, with management believing progress has been made[309](index=309&type=chunk)[310](index=310&type=chunk) [PART II. OTHER INFORMATION](index=63&type=section&id=PART%20II.%20OTHER%20INFORMATION) [Legal Proceedings](index=63&type=section&id=Item%201.%20Legal%20Proceedings) The company is involved in a class action lawsuit filed in March 2022, as detailed in Note 16, and other ordinary course litigation - The company is involved in legal proceedings, most notably a class action lawsuit described in Note 16 of the financial statements[315](index=315&type=chunk) [Risk Factors](index=63&type=section&id=Item%201A.%20Risk%20Factors) No material changes to risk factors have occurred since the 2021 Form 10-K filing - No material changes to risk factors have occurred since the 2021 Form 10-K filing[316](index=316&type=chunk) [Unregistered Sales of Equity Securities and Use of Proceeds](index=63&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) During Q3 2022, the company issued Class A common stock in unregistered transactions primarily for asset acquisitions and related fees - Issued **5,859,438** shares of Class A common stock on August 16, 2022, to Belen Health, LLC, pursuant to an asset purchase agreement[317](index=317&type=chunk) - Issued a total of **6,895,830** shares of Class A common stock in multiple unregistered transactions during Q3 2022 for acquisitions and related fees[317](index=317&type=chunk)[318](index=318&type=chunk)[319](index=319&type=chunk) [Other Information](index=65&type=section&id=Item%205.%20Other%20Information) There is no other information to report for this item - None[326](index=326&type=chunk) [Exhibits](index=65&type=section&id=Item%206.%20Exhibits) This section lists the exhibits filed with the Quarterly Report on Form 10-Q, including certifications by the CEO and CFO, and XBRL data files - The exhibit index lists all documents filed with or furnished as part of the report, including officer certifications and XBRL files[329](index=329&type=chunk)

| --- | --- | --- | |-------------------------------------------------------------------------------------------------------|---------|-------------------------------------| | | | | | Warrants to purchase one share of Class A common stock, each at an exercise | CANO/WS | The New York Stock Exchange | | price of $11.50 per share | | | UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 __________________________________________ FORM 10-Q __________________________________________ ☒ QUARTE ...

PART I FINANCIAL INFORMATION [Cautionary Note Regarding Forward-Looking Statements](index=3&type=section&id=Cautionary%20Note%20Regarding%20Forward-Looking%20Statements) Forward-looking statements in this report are subject to risks and uncertainties, and actual results may differ materially, with no obligation for updates - Statements regarding future events, financial performance, strategy, operations, and regulatory changes are forward-looking[8](index=8&type=chunk) - Risks include the ability to recognize business combination benefits, financial performance, regulatory changes, market share growth, and the impact of COVID-19[8](index=8&type=chunk) - Actual results may differ due to factors like NYSE listing maintenance, stock price volatility, industry competition, the need for additional capital, and difficulties in managing growth and expanding operations[11](index=11&type=chunk) [Item 1. Financial Statements](index=4&type=section&id=Item%201.%20Financial%20Statements) This section presents the company's unaudited condensed consolidated financial statements and detailed notes for Q1 2022 and FY 2021 [Condensed Consolidated Balance Sheets](index=6&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) The balance sheet shows the company's financial position as of March 31, 2022, compared to December 31, 2021, with key changes including decreased cash and increased accounts receivable | Metric (in thousands) | March 31, 2022 | December 31, 2021 | | :-------------------- | :------------- | :---------------- | | Cash, cash equivalents and restricted cash | $113,052 | $163,170 | | Accounts receivable, net | $191,724 | $133,433 | | Total assets | $2,171,765 | $2,143,539 | | Total liabilities | $1,333,988 | $1,344,971 | | Total Stockholders' Equity | $837,777 | $798,568 | [Condensed Consolidated Statements of Operations](index=7&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations) For Q1 2022, total revenue significantly increased, and net loss substantially reduced compared to Q1 2021, driven by higher capitated revenue and fair value changes | Metric (in thousands) | Three Months Ended March 31, 2022 | Three Months Ended March 31, 2021 | | :-------------------- | :-------------------------------- | :-------------------------------- | | Total revenue | $704,337 | $274,602 | | Loss from operations | $(11,456) | $(4,775) | | Net loss | $(85) | $(16,114) | | Net income attributable to Class A common stockholders | $660 | $0 | | Net income per share attributable to Class A common stockholders, basic | $0.00 | N/A | [Condensed Consolidated Statements of Stockholders' Equity / Members' Capital](index=8&type=section&id=Condensed%20Consolidated%20Statements%20of%20Stockholders'%20Equity%20/%20Members'%20Capital) Total stockholders' equity increased from December 31, 2021, to March 31, 2022, primarily due to additional paid-in capital from stock-based compensation and common stock issuance for acquisitions | Metric (in thousands) | March 31, 2022 | December 31, 2021 | | :-------------------- | :------------- | :---------------- | | Additional paid-in capital | $464,262 | $397,443 | | Accumulated deficit | $(78,100) | $(78,760) | | Total Stockholders' Equity | $837,777 | $798,568 | - Stock-based compensation expense contributed **$13,816 thousand** to additional paid-in capital[20](index=20&type=chunk) - Issuance of common stock for acquisitions added **$15,771 thousand** to additional paid-in capital[20](index=20&type=chunk) [Condensed Consolidated Statements of Cash Flows](index=9&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) For Q1 2022, the company experienced a net decrease in cash, cash equivalents, and restricted cash, primarily due to significant cash used in operating and investing activities | Metric (in thousands) | Three Months Ended March 31, 2022 | Three Months Ended March 31, 2021 | | :-------------------- | :-------------------------------- | :-------------------------------- | | Net cash used in operating activities | $(37,203) | $(14,688) | | Net cash used in investing activities | $(13,457) | $(9,699) | | Net cash provided by (used in) financing activities | $542 | $(2,818) | | Net decrease in cash, cash equivalents and restricted cash | $(50,118) | $(27,205) | | Cash, cash equivalents and restricted cash at end of period | $113,052 | $6,602 | - Non-cash investing and financing activities included **$26,364 thousand** for right-of-use assets obtained in exchange for lease liabilities and **$15,771 thousand** for issuance of Class A common stock for acquisitions[26](index=26&type=chunk) [Notes to Interim Condensed Consolidated Financial Statements](index=12&type=section&id=Notes%20to%20Interim%20Condensed%20Consolidated%20Financial%20Statements) This section provides detailed explanations and disclosures for the unaudited condensed consolidated financial statements, covering business nature, accounting policies, revenue, expenses, debt, fair value measurements, and other financial details [1. NATURE OF BUSINESS AND OPERATIONS](index=12&type=section&id=1.%20NATURE%20OF%20BUSINESS%20AND%20OPERATIONS) Cano Health provides value-based medical care through a network of primary care physicians, focusing on Medicare Advantage, DCE, ACO, and Medicaid members, particularly in underserved communities - Cano Health provides value-based medical care via primary care physicians in the U.S. and Puerto Rico, targeting Medicare Advantage, DCE, ACO, and Medicaid members[29](index=29&type=chunk) - The company's organizational structure is an Up-C corporation, with substantially all assets and operations held by PCIH and its subsidiaries[32](index=32&type=chunk)[33](index=33&type=chunk) - Cano Health, Inc. holds a **42.6% controlling ownership** in PCIH as of March 31, 2022, with non-controlling interests holding the remaining **57.4%**[32](index=32&type=chunk) [2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES](index=14&type=section&id=2.%20SUMMARY%20OF%20SIGNIFICANT%20ACCOUNTING%20POLICIES) This section reiterates that there were no significant changes to the company's accounting policies during Q1 2022, and mentions the adoption of ASU 2020-04 and the upcoming ASU 2021-08 - No significant changes to accounting policies during the three months ended March 31, 2022[47](index=47&type=chunk) - Adopted ASU 2020-04 (Reference Rate Reform), which did not impact net income[48](index=48&type=chunk) - Evaluating ASU 2021-08 (Business Combinations - Accounting for Contract Assets and Liabilities) effective January 1, 2023[49](index=49&type=chunk) [3. REVENUE AND ACCOUNTS RECEIVABLE](index=14&type=section&id=3.%20REVENUE%20AND%20ACCOUNTS%20RECEIVABLE) Total revenue for Q1 2022 significantly increased to **$704.3 million**, primarily driven by capitated revenue, especially from Medicare, with accounts receivable also increasing | Revenue Type (in thousands) | Three Months Ended March 31, 2022 | Revenue % (2022) | Three Months Ended March 31, 2021 | Revenue % (2021) | | :-------------------------- | :-------------------------------- | :--------------- | :-------------------------------- | :--------------- | | Capitated revenue (Total) | $674,351 | 95.7% | $261,357 | 95.2% | | - Medicare | $615,217 | 87.3% | $220,178 | 80.2% | | Fee-for-service and other revenue (Total) | $29,986 | 4.3% | $13,245 | 4.8% | | Total revenue | $704,337 | 100.0% | $274,602 | 100.0% | | Accounts Receivable (in thousands) | March 31, 2022 | December 31, 2021 | | :------------------------- | :------------- | :---------------- | | Accounts receivable, net | $191,724 | $133,433 | - Three payors accounted for **65.1%** of total revenue for the three months ended March 31, 2022[55](index=55&type=chunk) [4. UNPAID SERVICE PROVIDER COSTS](index=17&type=section&id=4.%20UNPAID%20SERVICE%20PROVIDER%20COSTS) Unpaid service provider costs significantly increased to **$222.1 million** as of March 31, 2022, primarily due to higher utilization rates, with the company using provider excess loss insurance to mitigate risk | Metric (in thousands) | March 31, 2022 | January 1, 2022 | | :-------------------- | :------------- | :-------------- | | Balance as of | $222,142 | $129,110 | | Incurred related to current year | $401,771 | N/A | | Paid related to current year | $207,279 | N/A | - Increase in estimate of **$3.3 million** for Q1 2022 due to higher utilization rates[58](

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 __________________________________________ FORM 10-K __________________________________________ ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to Commission File Number: 001-39289 ______________________________________ ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 __________________________________________ FORM 10-Q __________________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to __________________________________________ Cano Health, Inc. (E ...

Table of Contents Title of each class Trading Symbol(s) Name of each exchange on which registered Class A common stock, $0.0001 par value per share CANO The New York Stock Exchange Warrants to purchase one share of Class A common stock, each at an exercise price of $11.50 per share CANO/WS The New York Stock Exchange UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly per ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (MARK ONE) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarter ended March 31, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39289 JAWS ACQUISITION CORP. (Exact Name of Registrant as Specified in Its Charter) Cayman Islands 98-1524224 (State or o ...